We are live on ! Find out more
SCM

Sio Capital Management Portfolio holdings

AUM $697M
1-Year Est. Return 79.73%
This Fund
S&P 500
This Quarter Est. Return
-15.5%
1 Year Est. Return
+79.73%
3 Year Est. Return
+576.62%
5 Year Est. Return
+422.76%
10 Year Est. Return
+2,506.65%
AUM
$336M
AUM Growth
-$19.6M
Cap. Flow
+$53.2M
Cap. Flow %
15.83%
Top 10 Hldgs %
64.26%
Holding
65
New
14
Increased
15
Reduced
7
Closed
11

Top Buys

Rank Stock Value
1
MRK icon
Merck
MRK
+$25.3M
2
NBIX icon
Neurocrine Biosciences
NBIX
+$23.8M
3
GMED icon
Globus Medical
GMED
+$17.1M
4
EMBC icon
Embecta
EMBC
+$10.9M
5
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$9.49M

Top Sells

Rank Stock Value
1
CI icon
Cigna
CI
+$27.1M
2
SNY icon
Sanofi
SNY
+$18.7M
3
VTRS icon
Viatris
VTRS
+$9.09M
4
OGN icon
Organon & Co
OGN
+$9.05M
5
LH icon
Labcorp
LH
+$7.14M

Sector Composition

Rank Sector Weight
1 Healthcare 88.81%
2 Industrials 9.51%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VIR icon
26
Vir Biotechnology
VIR
$1.48B
$3.07M 0.91%
473,607
-581,044
-55% -$5.17M
AORT icon
27
Artivion
AORT
$1.33B
$2.98M 0.89%
121,178
– –
VTYX
28
DELISTED
Ventyx Biosciences
VTYX
$2.97M 0.88%
2,582,655
-1,464,142
-36% -$2.51M
PRQR icon
29
ProQR Therapeutics
PRQR
$271M
$2.73M 0.81%
2,054,593
– –
VXRT
30
DELISTED
Vaxart
VXRT
$2.27M 0.68%
5,583,448
-5,931,867
-52% -$3.8M
TVTX icon
31
Travere Therapeutics
TVTX
$6B
$2.17M 0.65%
+121,000
New +$2.46M
DNTH icon
32
Dianthus Therapeutics
DNTH
$6.03B
$2.12M 0.63%
+116,997
New +$2.58M
IDYA icon
33
IDEAYA Biosciences
IDYA
$3.49B
$2.01M 0.6%
123,000
– –
SVRA icon
34
Savara
SVRA
$1.18B
$1.99M 0.59%
719,654
+715,907
+19,106% +$1.98M
ERAS icon
35
Erasca
ERAS
$6.35B
$1.86M 0.55%
1,356,186
– –
ATXS
36
DELISTED
Astria Therapeutics
ATXS
$1.68M 0.5%
315,105
-189,782
-38% -$1.33M
IRWD icon
37
Ironwood Pharmaceuticals
IRWD
$691M
$1.5M 0.45%
1,017,616
+109,833
+12% +$262K
ALGS icon
38
Aligos Therapeutics
ALGS
$33.1M
$1.49M 0.44%
+180,720
New +$3.96M
AQST icon
39
Aquestive Therapeutics
AQST
$483M
$1.14M 0.34%
+391,629
New +$1.19M
ALEC icon
40
Alector
ALEC
$207M
$1.03M 0.31%
837,159
+221,531
+36% +$361K
ENTA icon
41
Enanta Pharmaceuticals
ENTA
$386M
$977K 0.29%
177,004
– –
CNTX icon
42
Context Therapeutics
CNTX
$46.1M
$813K 0.24%
1,328,352
– –
TELA icon
43
TELA Bio
TELA
$38.3M
$769K 0.23%
630,000
– –
OVID icon
44
Ovid Therapeutics
OVID
$485M
$696K 0.21%
2,232,000
+1,232,000
+123% +$758K
AVTX icon
45
Avalo Therapeutics
AVTX
$974M
$572K 0.17%
71,458
– –
APRE icon
46
Aprea Therapeutics
APRE
$7.94M
$564K 0.17%
276,603
– –
FHTX icon
47
Foghorn Therapeutics
FHTX
$325M
$444K 0.13%
121,672
– –
NYXH
48
Nyxoah
NYXH
$132M
$355K 0.11%
50,839
– –
MODD icon
49
Modular Medical
MODD
$11.2M
$275K 0.08%
8,400
– –
BOLD
50
Boundless Bio
BOLD
$64.7M
$245K 0.07%
162,058
– –
1
2
3

Similar funds

GUB
Golden Unicorn BVI Road Town $697M AUM 55.92% 1-Year Est. Return
KLI
Kelman-Lazarov Inc Memphis, Tennessee $698M AUM 14.07% 1-Year Est. Return
JA
JLB & Associates Plymouth, Michigan $696M AUM 17.86% 1-Year Est. Return
AAM
Auxier Asset Management Aurora, Oregon $696M AUM 18.07% 1-Year Est. Return
TCM
Tensile Capital Management Larkspur, California $698M AUM 2.4% 1-Year Est. Return
CA
Calton & Associates Tampa, Florida $696M AUM 18.3% 1-Year Est. Return
SAM
Silverback Asset Management Chapel Hill, North Carolina $699M AUM 72.42% 1-Year Est. Return
ACM
Academy Capital Management Waco, Texas $699M AUM 12.08% 1-Year Est. Return

Sio Capital Management's Q1 2025 Portfolio in Review

As of Q1 2025, Sio Capital Management held 65 positions worth $336M, down 5.5% from $355M the previous quarter. Its ten largest holdings account for 64% of the portfolio.

Sio Capital Management deployed $53.2M of net new capital in Q1 2025, opening 14 new positions and adding to 15 existing holdings. Its largest new stake was Merck: 270,596 shares worth $24.3M.

By sector, the portfolio is most concentrated in Healthcare at 89% of assets, down from 92% a quarter earlier, followed by Industrials.

On the sell side, the largest reduction was Labcorp, an estimated $7.14M trimmed.

  • Sio Capital Management's largest Q1 2025 buy was Merck: 270,596 shares worth $24.3M.
  • Sio Capital Management added most to Embecta in Q1 2025, an estimated $10.9M increase.
  • Sio Capital Management's biggest Q1 2025 reduction was Labcorp, cutting an estimated $7.14M.
  • Sio Capital Management fully exited Cigna in Q1 2025, selling an estimated $27.1M.
  • Sio Capital Management's ten largest holdings make up 64% of its $336M portfolio in Q1 2025.
  • Sio Capital Management opened 14 new positions and closed 11 in Q1 2025.
  • Sio Capital Management's portfolio value fell 5.5% quarter-over-quarter to $336M.

Based on Sio Capital Management's 13F filing for Q1 2025, filed 15 May 2025.